Oppenheimer Weighs in on Frequency Therapeutics, Inc.’s Q3 2022 Earnings (NASDAQ:FREQ)

Frequency Therapeutics, Inc. (NASDAQ:FREQGet Rating) – Equities researchers at Oppenheimer issued their Q3 2022 EPS estimates for shares of Frequency Therapeutics in a research report issued to clients and investors on Monday, May 9th. Oppenheimer analyst J. Olson anticipates that the company will earn ($0.77) per share for the quarter.

Separately, B. Riley reduced their price objective on Frequency Therapeutics from $17.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, March 23rd.

Shares of FREQ stock opened at $1.40 on Wednesday. Frequency Therapeutics has a 12 month low of $1.16 and a 12 month high of $10.90. The company has a debt-to-equity ratio of 0.10, a quick ratio of 11.79 and a current ratio of 9.85. The company’s 50 day moving average is $1.82. The firm has a market capitalization of $48.97 million, a P/E ratio of -0.55 and a beta of 0.96.

Frequency Therapeutics (NASDAQ:FREQGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.03).

A number of hedge funds have recently modified their holdings of FREQ. Tortoise Investment Management LLC bought a new position in Frequency Therapeutics in the first quarter worth $27,000. Duncker Streett & Co. Inc. bought a new position in shares of Frequency Therapeutics during the first quarter valued at $33,000. Citigroup Inc. lifted its holdings in shares of Frequency Therapeutics by 56.6% during the fourth quarter. Citigroup Inc. now owns 9,203 shares of the company’s stock valued at $47,000 after acquiring an additional 3,325 shares during the period. Allspring Global Investments Holdings LLC bought a new position in shares of Frequency Therapeutics during the first quarter valued at $54,000. Finally, Renaissance Technologies LLC bought a new position in shares of Frequency Therapeutics during the fourth quarter valued at $69,000. 50.64% of the stock is owned by hedge funds and other institutional investors.

About Frequency Therapeutics (Get Rating)

Frequency Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue.

Featured Articles

Earnings History and Estimates for Frequency Therapeutics (NASDAQ:FREQ)

Receive News & Ratings for Frequency Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frequency Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.